Methylene blue treatment in experimental ischemic stroke: A mini-review

Stroke is among the leading causes of death and long-term disability. Methylene blue (MB), a drug grandfathered by the Food and Drug Administration with a long history of safe usage in humans for treating methemoglobinemia and cyanide poisoning, has recently been shown to be neuroprotective in neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Zhao, Duong, Timothy Q
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2016
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817094/
https://www.ncbi.nlm.nih.gov/pubmed/27042692
http://dx.doi.org/10.4103/2394-8108.178548
Descripción
Sumario:Stroke is among the leading causes of death and long-term disability. Methylene blue (MB), a drug grandfathered by the Food and Drug Administration with a long history of safe usage in humans for treating methemoglobinemia and cyanide poisoning, has recently been shown to be neuroprotective in neurodegenerative diseases and brain injuries. The goal of this paper is to review studies on MB in experimental stroke models.

Ejemplares similares